Bio Business

» disease/medicine and regulation

Most Recent

image: Making CAR T-Cell Therapy Safer

Making CAR T-Cell Therapy Safer

By | April 1, 2017

Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.

0 Comments

image: Pharma Cooperates to Achieve Precision Medicine

Pharma Cooperates to Achieve Precision Medicine

By | February 1, 2017

The challenges of adapting drug development to the age of personalized therapies encourage collaboration among industry players.

0 Comments

image: Oligonucleotide Therapeutics Near Approval

Oligonucleotide Therapeutics Near Approval

By | December 1, 2016

Successful late-stage clinical trials could mark the maturation of a new drug development platform, but the path to commercialization is not without hurdles.

0 Comments

image: Pet Meds Adapted from Human Therapies

Pet Meds Adapted from Human Therapies

By | October 1, 2016

Companies focused on developing treatments for dogs, cats, and horses are bringing a diverse array of products to the pet medicine market.

0 Comments

image: Desperately Seeking Shut-Eye

Desperately Seeking Shut-Eye

By | March 1, 2016

New insomnia drugs are coming on the market, but drug-free therapy remains the most durable treatment.

0 Comments

image: Picking Up the Pace

Picking Up the Pace

By | January 1, 2016

FDA designations promise to expedite the approval of drugs for conditions ranging from infectious disease to cancer.

0 Comments

image: Battling the Bulge

Battling the Bulge

By | November 1, 2015

Weight-loss drugs that target newly characterized obesity-related receptors and pathways could finally offer truly effective fat control.

0 Comments

image: Clinical Matchmaker

Clinical Matchmaker

By | June 1, 2015

Enrolling the right patient population could be key to a successful clinical trial.

0 Comments

image: The CAR T-Cell Race

The CAR T-Cell Race

By | April 1, 2015

Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way.

2 Comments

image: Lazarus Drugs

Lazarus Drugs

By | February 1, 2015

While some drugs sail through development, others suffer setbacks, including FDA rejections, before reaching the market.  

1 Comment

Popular Now

  1. Long-term Study Finds That the Pesticide Glyphosate Does Not Cause Cancer
  2. Man Receives First In Vivo Gene-Editing Therapy
  3. Researchers Build a Cancer Immunotherapy Without Immune Cells
  4. Child Receives Transgenic Skin Over Most of His Body
RayBiotech